Moderna's market value jumped by more than 30 billion dollars this week after the company announced positive results for its melanoma vaccine, and the math behind that jump is genuinely wild. A Reuters Breakingviews analysis works out what investors are actually pricing in, and it isn't one successful drug. To justify a gain that size you need annual sales somewhere around 13 billion dollars a year, which is roughly what a whole portfolio of blockbuster cancer treatments earns, not a single indication.

So, backing up. The vaccine targets melanoma recurrence, it's built on Moderna's mRNA platform, and it trains the immune system to attack the specific mutations on a patient's own tumor. This is personalized neoantigen therapy, the thing researchers have been promising since mRNA tech proved itself during the pandemic. Each dose is essentially custom-manufactured for one person's cancer. As someone who spends his days writing software, the idea of a treatment pipeline that has to compile a unique biological artifact per patient makes my build times feel very reasonable.

The clinical signal matters here. Preventing recurrence in melanoma patients after surgery is a real endpoint, not a proxy, and melanoma is one of the most mutation-heavy cancers out there, which is exactly the kind of tumor this approach should work best against. It's the friendly test case. Whether the same platform scales to cancers with fewer mutations is the harder question, pancreatic being the notorious villain there.

And that's the part the market seems to be ignoring a little. A 13 billion dollar annual sales figure implies the melanoma result is a proof of concept for a whole family of cancer vaccines, that this works broadly and repeatedly. Which is possible! The mRNA machinery is the same across indications, only the antigen target changes, so marginal development cost per new cancer type should be lower than a from-scratch drug. The platform logic is sound. It's the same reason Nvidia can sell the same chip architecture into a dozen markets.

But platform logic has a failure mode I see constantly in software: the demo that works beautifully on the happy path and falls apart on weird edge cases. Melanoma with its massive mutation load is the happy path. Tumors that look genetically bland to the immune system are the edge cases, and there are a lot of them.

There's also the manufacturing question. A vaccine custom-built per patient can't be churned out like a flu shot. Throughput, turnaround time from biopsy to dose, cost per patient, these all constrain the revenue ceiling well below what a generic blockbuster earns. Reuters points out that even optimistic adoption scenarios need the price per course and the eligible patient population to cooperate, and insurers are not famous for cooperating.

None of this is a bet against the science. The melanoma data, coming on top of the survival numbers Moderna and Merck have reported from earlier trials, suggests mRNA oncology is real in a way that felt speculative five years ago. My skepticism is purely about the price tag. Markets have a habit of pricing in the entire future of a platform the moment one component of it works, and biotech history is a graveyard of platforms that delivered one good drug and then plateaued.

I'll be watching the next readouts in additional indications, because those are the trials that decide whether investors bought a vaccine or bought a fantasy. If the pancreatic or lung data lands well, this valuation starts looking conservative. If it doesn't, a 30 billion dollar gain can evaporate faster than a bad merge into main.